# Bluestar-Endometrial01 (NCT07044336)

> Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

No report yet. It can be ordered.

- Drugs tested: puxitatug samrotecan (AZD8205)
- Indication: B7-H4-selected advanced/metastatic endometrial cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07044336
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: AstraZeneca
- Conditions: Endometrial Cancer; Malignant Solid Tumour
- Interventions: Puxitatug Samrotecan; Doxorubicin; Paclitaxel
- Enrollment: 800
- Primary outcome: Progression Free Survival (PFS) for Arm A vs Arm B
- Primary outcome: Overall survival (OS) for Arm A vs Arm B

## Indexed commentary on Bluestar-Endometrial01 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 YouTube videos
- 1 podcast episode
- 1 post on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=bluestar-endometrial01-nct07044336
